ATAI Life Sciences nets $43 mln Series B
ATAI Life Sciences, a global biotech platform focused on curing mental health disorders, has raised $43 million in Series B financing. Subversive Capital led the round.
28 March 2019•1 min read
ATAI Life Sciences, a global biotech platform focused on curing mental health disorders, has raised $43 million in Series B financing. Subversive Capital led the round.
